Skip to main content

Table 1 Comparison of demographic and clinical characteristics between patients with / without gastric cancer recurrence

From: CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

Characteristics

Study Group

Control Group

 P -value

 

(n = 20)

(n = 20)

 
 

Recurrence

Non-recurrence

 

Gender, n(%)

Male

12 (60.0)

7 (35.0)

0.113†

Female

8 (40.0)

13 (65.0)

 

Age (years)

mean ± SD

71.2 ± 10.6

65.7 ± 11.7

0.128‡

Age group, n(%)

≤65

6 (30.0)

10 (50.0)

0.197†

>65

14 (70.0)

10 (50.0)

 

Histology, n(%)

Moderately differentiated (intestinal type)

9 (45.0)

6 (30.0)

0.327†

Poorly differentiated (diffuse type)

11 (55.0)

14 (70.0)

 

Tumor location, n(%)

Upper third of stomach

5 (25.0)

10 (50.0)

0.191¶

Middle third of stomach

1 (5.0)

0 (0.0)

 

Lower third of stomach

14 (70.0)

10 (50.0)

 

TNM Stage, n(%)

I-IIa

4 (20.0)

15 (75.0)

0.001*†

III-IV

16 (80.0)

5 (25.0)

 

Lymph node metastasis, n(%)

No

2 (10.0)

11 (55.0)

0.002*†

Yes

18 (90.0)

9 (45.0)

 

Number of lymph node metastasis, n(%)

0

2 (10.0)

11 (55.0)

0.007*†

1-4 s

9 (45.0)

6 (30.0)

 

≥5

9 (45.0)

3 (15.0)

 

CD44 expression, n(%)

CD44-

10 (50.0)

10 (50.0)

1.000†

CD44+

10 (50.0)

10 (50.0)

 

CD24 expression, n(%)

CD24-

10 (50.0)

13 (65.0)

0.337†

CD24+

10 (50.0)

7 (35.0)

 

CD44 / CD24 expression, n(%)

CD44-/CD24-

5 (25.0)

8 (40.0)

0.622¶

CD44-/CD24+

5 (25.0)

2 (10.0)

 

CD44+/CD24-

5 (25.0)

5 (25.0)

 

CD44+/CD24+

5 (25.0)

5 (25.0)

 
  1. a Two control patients with TNM Stage 0 were grouped into Stage I-II.
  2. *P<0.05.
  3. † Chi-square test; ‡ independent t-test; ¶Fisher’s exact test.